Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Inhibikase Therapeutics (IKT) Income from Continuing Operations (2020 - 2025)

Inhibikase Therapeutics (IKT) has disclosed Income from Continuing Operations for 6 consecutive years, with 13775626.0 as the latest value for Q4 2025.

  • Quarterly Income from Continuing Operations fell 6.55% to 13775626.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 51974283.0 through Dec 2025, down 81.8% year-over-year, with the annual reading at 51974283.0 for FY2025, 81.8% down from the prior year.
  • Income from Continuing Operations for Q4 2025 was 13775626.0 at Inhibikase Therapeutics, down from 12768373.0 in the prior quarter.
  • The five-year high for Income from Continuing Operations was 2636179.0 in Q2 2021, with the low at 14598006.0 in Q1 2025.
  • Average Income from Continuing Operations over 5 years is 6677464.3, with a median of 4775618.0 recorded in 2023.
  • The sharpest move saw Income from Continuing Operations tumbled 566.75% in 2021, then increased 18.57% in 2024.
  • Over 5 years, Income from Continuing Operations stood at 5041619.0 in 2021, then grew by 14.02% to 4334974.0 in 2022, then fell by 1.58% to 4403566.0 in 2023, then crashed by 193.6% to 12928700.0 in 2024, then decreased by 6.55% to 13775626.0 in 2025.
  • According to Business Quant data, Income from Continuing Operations over the past three periods came in at 13775626.0, 12768373.0, and 10832278.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.